Company intelligence / Profile preview

Vicinitas Therapeutics

South San Francisco, California, United Statesvicinitas.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Vicinitas Therapeutics has demonstrated preclinical proof-of-concept for its DUBTAC technology, showing the ability to stabilize disease-relevant proteins such as those involved in cystic fibrosis and tumor suppression. No clinical results have been reported as of May 2025; all programs are at the discovery or preclinical stage.[6][8]

Therapeutic areas: OncologyRare DiseasesOther
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

WEE1-targeting DUBTAC

Preclinical

Partnerships

Novartis Institutes for BioMedical Research (academic-industry collaboration with UC Berkeley that led to company formation and ongoing research partnership)[3][4][6]

Beyond the preview

Go deeper on Vicinitas Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vicinitas Therapeutics.

Explore the full profile